Zevra Therapeutics: A Measured Long for Patient-Driven Growth and Cash Strength
Zevra (ZVRA) is a commercial-stage rare disease company with a newly approved therapy for Niemann-Pick disease type C and recurring royalty income. The stock trades at a single-digit P/E and below $800M market cap, creating a risk/reward setup for an initial long position. This idea outlines an entry, stop, target and the catalysts and risks that s…